Related Experiment Video
Updated: Aug 1, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Preclinical evaluation of lovastatin
J S MacDonald1, R J Gerson, D J Kornbrust
1Department of Safety Assessment, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
Abstract:
Administration of lovastatin to animals at high dosage levels produces a broad spectrum of toxicity. This toxicity is expected based on the critical nature of the target enzyme (HMG CoA reductase) and the magnitude of the dosage levels used. The information reviewed in this paper demonstrates that these adverse findings in animals do not predict significant risk in humans. The reason for this derives from the fact that all the available evidence suggests that the adverse effects observed are produced by an exaggeration of the desired biochemical effect of the drug at high dosage levels. The presence of clear and high no-effect doses for these toxic effects along with the fact that most of the changes observed are clearly mechanism-based (directly attributable to inhibition of mevalonate synthesis) indicate that it is unlikely that similar changes will be observed at the therapeutic dosage levels in humans. This hypothesis is supported by the extensive human safety experience described by Tobert in the following report.
Insights
High-dose lovastatin causes toxicity in animals by over-inhibiting HMG CoA reductase. However, this animal toxicity does not predict human risk at therapeutic doses due to mechanism-based effects.
Area of Science:
- Pharmacology
- Toxicology
- Biochemistry
Background:
- Lovastatin targets HMG CoA reductase, an enzyme crucial for cholesterol synthesis.
- High-dose lovastatin administration in animals results in a wide range of toxicities.
Purpose of the Study:
- To evaluate the relevance of animal toxicity findings to human safety.
- To determine if adverse effects observed in animals predict significant risks in humans.
Main Methods:
- Review of existing toxicological data from animal studies.
- Analysis of the biochemical mechanism underlying lovastatin-induced toxicity.
- Comparison of high-dose animal effects with therapeutic human dosage levels.
Main Results:
- Animal toxicities are linked to an exaggerated pharmacological effect of lovastatin.
- Clear no-effect doses were identified for observed toxicities in animals.
- Adverse effects are mechanism-based, directly related to mevalonate synthesis inhibition.
Conclusions:
- Animal toxicity findings at high doses do not indicate significant human risk.
- Mechanism-based toxicity suggests a low likelihood of adverse effects at therapeutic human doses.
- Extensive human safety data supports the low risk profile of lovastatin in humans.
Related Concept Videos
01:28Preclinical Development: Overview
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:29Therapeutic Drug Monitoring: Affecting Factors
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Atherosclerosis III: Management